ARTICLE | Management Tracks
Kevin Bunker promoted to CSO at Zentalis
Plus Fonck becomes partner at Pureos, and updates from 4D Molecular, Gandeeva, Code and more
September 29, 2022 12:32 AM UTC
Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) promoted COO Kevin Bunker to CSO. Bunker, a company co-founder, has been leading R&D at Zentalis since the company’s formation. Previously, he co-founded Kalyra Pharmaceuticals Inc. and worked in the drug discovery research group at Pfizer Inc. (NYSE:PFE). Zentalis is developing small molecules to treat cancer.
Veronica Fonck will become a partner at Pureos Partners, a venture capital arm of Pureos Bioventures, on Oct. 1. Fonck was CEO at GlycoEra AG and LimmaTech Biologics AG, companies that she co-founded. ...